Search results for " pulmonary disease"

showing 10 items of 137 documents

Airway obstruction in relation to symptoms in chronic respiratory disease—a nationally representative population study

2000

Abstract We examined the severity of airway obstruction and the occurrence of respiratory symptoms in a large, nationally representative population sample and in a subgroup of subjects with chronic bronchitis and/or emphysema to obtain information for developing national prevention and treatment strategies for these diseases. The study population comprised of 7217 randomly selected subjects (aged 30 years and older) who participated in a comprehensive health examination survey. The ‘cases' were subjects diagnosed as having chronic bronchitis and/or emphysema. The survey methods comprised of questionnaires, interviews, physical measurements, including spirometry, and clinical examinations. I…

SpirometryAdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyChronic bronchitissymptoms.chronic obstructive pulmonary diseaseFEV1/FVC ratioInternal medicineForced Expiratory VolumeSurveys and QuestionnairesOdds RatioPrevalenceMedicineHumansLung Diseases ObstructiveBronchitisFinlandAgedEmphysemamedicine.diagnostic_testbusiness.industryPhlegmRespiratory diseaseSmokinglung functionAirway obstructionMiddle Agedrespiratory systemmedicine.diseaseobstructionrespiratory tract diseasesCold TemperatureChronic coughDyspneaPopulation SurveillanceChronic DiseasePhysical therapyPopulation studychronic bronchitisFemalemedicine.symptombusinessRespiratory Medicine
researchProduct

The airway response to deep inspirations decreases with COPD severity and is associated with airway distensibility assessed by computed tomography.

2008

In patients with mild chronic obstructive pulmonary disease (COPD), the effect of deep inspirations (DIs) to reverse methacholine-induced bronchoconstriction is largely attenuated. In this study, we tested the hypothesis that the effectiveness of DI is reduced with increasing disease severity and that this is associated with a reduction in the ability of DI to distend the airways. Fifteen subjects [Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I–II: n = 7; GOLD stage III–IV: n = 8] underwent methacholine bronchoprovocation in the absence of DI, followed by DI. The effectiveness of DI was assessed by their ability to improve inspiratory vital capacity and forced expira…

SpirometryHigh-resolution computed tomographyPhysiologyRespiratory SystemVital CapacityHyperinflationSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexBronchial Provocation TestsBronchoconstrictor AgentsAirway-parenchyma interdependencePulmonary Disease Chronic ObstructiveBronchoprovocationPhysiology (medical)Forced Expiratory VolumeSeverity of illnessAdministration InhalationmedicineHumansHigh-resolution computed tomographyMethacholine ChlorideAgedAged 80 and overCOPDMethacholinemedicine.diagnostic_testbusiness.industryAirway-parenchyma interdependence; Bronchoprovocation; High-resolution computed tomography; Hyperinflation; Methacholine; Administration Inhalation; Aged; Aged 80 and over; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoconstrictor Agents; Elasticity; Forced Expiratory Volume; Humans; Methacholine Chloride; Middle Aged; Pulmonary Disease Chronic Obstructive; Respiratory System; Severity of Illness Index; Spirometry; Vital Capacity; Inhalation; Tomography Spiral Computed; Physiology; Physiology (medical)Respiratory diseaseArticlesrespiratory systemMiddle Agedmedicine.diseaseElasticityrespiratory tract diseasesBronchial Provocation TestInhalationSpirometryAnesthesiaBronchoconstrictor AgentBronchoconstrictionMethacholinemedicine.symptomBronchial HyperreactivityAirwaybusinessTomography Spiral ComputedHumanmedicine.drugJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

Extracellular vesicles in airway homeostasis and pathophysiology

2021

The epithelial–mesenchymal trophic unit (EMTU) is a morphofunctional entity involved in the maintenance of the homeostasis of airways as well as in the pathogenesis of several diseases, including asthma and chronic obstructive pulmonary disease (COPD). The “muco-microbiotic layer” (MML) is the innermost layer of airways made by microbiota elements (bacteria, viruses, archaea and fungi) and the surrounding mucous matrix. The MML homeostasis is also crucial for maintaining the healthy status of organs and its alteration is at the basis of airway disorders. Nanovesicles produced by EMTU and MML elements are probably the most important tool of communication among the different cell types, inclu…

TechnologyCell typenanovesiclesQH301-705.5QC1-999Asthma Chronic obstructive pulmonary diseaseCOPDEpithelial–mesenchymal trophic unitExosomesMicrobiota Muco-microbiotic layer nanovesicles Outer membrane vesicles.Biologychronic obstructive pulmonary diseasePathogenesismedicineCOPDGeneral Materials ScienceBiology (General)QD1-999InstrumentationAsthmaFluid Flow and Transfer ProcessesCOPDSettore BIO/16 - Anatomia UmanaTPhysicsProcess Chemistry and TechnologyGeneral EngineeringasthmaEngineering (General). Civil engineering (General)medicine.diseasemuco-microbiotic layerMicrovesiclesPathophysiologyrespiratory tract diseasesComputer Science ApplicationsChemistryepithelial–mesenchymal trophic unitImmunologyTA1-2040AirwayHomeostasis
researchProduct

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

2012

Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are the main classes of long-acting bronchodilators. To date, tiotropium is the only once-daily LAMA available for the treatment of COPD. Glycopyrronium is a novel LAMA, currently in development for COPD. Phase II studies have shown that glycopyrronium 50 μg once daily provides clinically significant 24-hour bronchodilation with a rapid onset of action, which is faster than that of tiotropium, and a favorable safety and tolerability profile. The Phase III GLycopyrronium bromide in COPD airWays (GLOW) progr…

Time FactorsCombination therapymuscarinic antagonistReviewMuscarinic AntagonistsPlaceboNVA237Severity of Illness IndexDrug Administration Schedulechronic obstructive pulmonary diseaseglycopyrroniumPulmonary Disease Chronic ObstructiveAdministration InhalationHumansMedicineGlycopyrronium bromideAdverse effectLungCOPDExercise Tolerancebiologybusiness.industryGeneral MedicineLamamedicine.diseasebiology.organism_classificationonce dailyGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeTolerabilityAnesthesiaIndacaterolbusinessmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life

2016

Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University of G…

Time FactorsReviewdaily symptomsAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineBronchodilatorMedicine030212 general & internal medicineLungCOPDHealth PolicyTropaneLAMAGeneral MedicineBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeTolerabilityChronic inflammatory responsePublic HealthHumanPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyTime Factormedicine.drug_classBronchoconstrictionSocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesAclidinium bromideaclidiniumAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Bronchoconstriction; Bronchodilator Agents; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome; Tropanes; Quality of LifeInternal medicineSeverity of illnessAnticholinergicCOPDHumansAdverse effectBronchodilator Agentlcsh:RC705-779business.industryEnvironmental and Occupational HealthDaily symptomPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemRecovery of Functionmedicine.diseasequality of life030228 respiratory systemPhysical therapybusinessTropanesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine.

2012

Persistent respiratory syncytial virus (RSV) infections have been associated with the exacerbation of chronic inflammatory diseases, including chronic obstructive pulmonary disease (COPD). This virus infects the respiratory epithelium, leading to chronic inflammation, and induces the release of mucins and the loss of cilia activity, two factors that determine mucus clearance and the increase in sputum volume. These alterations involve reactive oxygen species-dependent mechanisms. The antioxidant N-acetylcysteine (NAC) has proven useful in the management of COPD, reducing symptoms, exacerbations, and accelerated lung function decline. NAC inhibits RSV infection and mucin release in human A54…

Viral DiseasesPulmonologyChronic Obstructive Pulmonary Diseaseslcsh:MedicineMucin 5ACVirus ReplicationAcetylcysteinePulmonary Disease Chronic ObstructiveTubulinRespiratory systemlcsh:ScienceCells CulturedMultidisciplinaryInterleukin-13Microscopy VideoCell DifferentiationForkhead Transcription FactorsFree Radical Scavengersrespiratory systemHost-Pathogen InteractionLower Respiratory Tract InfectionsInfectious Diseasesmedicine.anatomical_structureInterleukin 13Medicinemedicine.symptomResearch Articlemedicine.drugDrugs and DevicesInflammationBronchiRespiratory Syncytial Virus InfectionsBiologyMicrobiologyAntiviral AgentsUpper Respiratory Tract InfectionsmedicineHumansCiliaBiologyInflammationRespiratory Syncytial Virus InfectionA549 cellMucinlcsh:RImmunityEpithelial CellsAxonemal DyneinsEpitheliumAcetylcysteineGene Expression RegulationRespiratory Syncytial Virus HumanRespiratory InfectionsImmunologyRespiratory epitheliumlcsh:QPLoS ONE
researchProduct

Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI.

2009

Chronic obstructive pulmonary disease (COPD) patients have reduced circulating hemopoietic progenitors. We hypothesized that severity of COPD parallels the decrease in progenitors and that the reduction in body mass index (BMI) could be associated with more severe bone marrow dysfunction. We studied 39 patients with moderate to very severe COPD (18 with low-BMI and 21 with normal-BMI) and 12 controls. Disease severity was associated to a greater reduction in circulating progenitors. Proangiogenetic and inflammatory markers correlated with disease severity parameters. Compared to normal-BMI patients, low-BMI patients showed: greater reduction in circulating progenitors; higher VEGF-A, VEGF-C…

aged; analysis of variance; antigens; blood; blood cell count; body mass index; bone marrow transplantation; case-control studies; cd; chronic obstructive; chronic obstructive pulmonary disease; colony-forming units assay; creatine kinase; cytokines; endothelial cells; enzyme-linked immunosorbent assay; fat-free mass; female; humans; intercellular signaling peptides and proteins; lactate dehydrogenases; low-bmi copd; male; metabolism; methods; middle aged; normal-bmi copd; physiology; physiopathology/surgery; pulmonary disease; severity of illness index; statistics as topicMalePathologyPhysiologyStatistics as TopicCD34GastroenterologySeverity of Illness IndexBody Mass IndexPulmonary Disease Chronic Obstructiveantigenslow-bmi copdnormal-bmi copdCreatine Kinasepulmonary diseaseBone Marrow TransplantationCOPDchronic obstructiveGeneral NeuroscienceRespiratory diseaseMiddle Agedcdfat-free massHaematopoiesismedicine.anatomical_structurephysiopathology/surgeryCytokinesIntercellular Signaling Peptides and ProteinsFemalePulmonary and Respiratory Medicinemedicine.medical_specialtyEnzyme-Linked Immunosorbent Assaymacromolecular substancesSettore MED/10 - Malattie Dell'Apparato Respiratoriochronic obstructive pulmonary diseasemethodsColony-Forming Units AssayChronic obstructive pulmonary disease low-BMI COPD normal-BMI COPD fat-free massbloodAntigens CDInternal medicineSeverity of illnessmedicineHumansProgenitor cellLactate DehydrogenasesAgedAnalysis of Variancebusiness.industryCase-control studyEndothelial Cellsmedicine.diseaseBlood Cell CountCase-Control StudiesBone marrowbusinessmetabolismRespiratory physiologyneurobiology
researchProduct

Biomarkers in obstructive respiratory diseases: An update

2012

Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation of the airways, with the involvement of many inflammatory cells and mediators. Traditionally, this inflammation is thought to spread to a systemic level, thus inducing damage of different organs. However, other pathogenetic mechanisms could take part to the above-described process, and some open questions need to be solved. Due to the burden and increasing prevalence of COPD, the opportunity to find biomarkers that can potentially be useful in identifying individuals with the disease, or better, prior to symptoms onset, to diagnose and properly manage the respiratory symptoms, as well as to evaluate the re…

chronic obstructiveSputumBiomarkerSettore MED/10 - Malattie Dell'Apparato RespiratorioOutcome assessmentPulmonary Disease Chronic ObstructiveC-Reactive ProteinForced Expiratory VolumeHumansUteroglobinPulmonary diseaseBiomarkersHumanBiomarkers; Pulmonary disease chronic obstructive; Outcome assessment
researchProduct

Burden of Comorbidities in Patients with OSAS and COPD-OSAS Overlap Syndrome

2021

Background and Objectives: Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease (COPD) are usually associated with multi-morbidity. The aim of this study was to retrospectively investigate the prevalence of comorbidities in a cohort of patients with OSAS and COPD-OSAS overlap syndrome (OS) patients and to explore differences between these two groups. Materials and Methods: Included were consecutive OS patients and OSAS patients who had been referred to our sleep laboratory, and were matched in terms of sex, age, BMI, and smoking history. Presence of comorbidities was recorded based on their medical history and after clinical and laboratory examination. Results: …

comorbiditiemedicine.medical_specialtyMedicine (General)obstructive sleep apnea syndromeComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratoriooverlap syndromecomorbiditiesArticlechronic obstructive pulmonary diseaseFEV1/FVC ratioPulmonary Disease Chronic ObstructiveR5-920cardiovascular diseaseInternal medicinemedicineHumansRetrospective StudiesCOPDSleep Apnea Obstructivebusiness.industryOverlap syndromeGeneral Medicinemedicine.diseaseComorbiditynervous system diseasesRespiratory Function Testsrespiratory tract diseasesObstructive sleep apneaApnea–hypopnea indexCohortbusinessDyslipidemiaMedicina
researchProduct

The difference in risk of chronic pulmonary disease morbidity and mortality between elite athletes and ordinary men in Finland

2020

Introduction: The impact of a history of competitive sports on later smoking behavior and occurrence of chronic pulmonary diseases is poorly known. We investigated how a history of elite level sports predicted later pulmonary disease morbidity and mortality. Methods: Chronic pulmonary disease incidence were assessed from national hospital and cause-of-death registers from 1970 to 2015 among Finnish male former elite athletes (n=2078) and matched controls (n=1453) alive in 1970 (mean age 45.0 years). Hazard ratios (HRs) were calculated by Cox proportional hazards model. In 1985, cohort members reported on their smoking habits, engagement in physical activity/sports and physician-diagnosed ch…

former athlete(s)physical activitycopdasthmasmokingemphysemaobstructive pulmonary diseasetupakointiastmacohort studychronic bronchitiskeuhkosairaudetkeuhkoahtaumatautikrooniset tauditchronic diseasefyysinen aktiivisuusurheilijat
researchProduct